Literature DB >> 11570304

Current management of acute ischemic stroke. Part 1: Thrombolytics and the 3-hour window.

A M Herd1.   

Abstract

OBJECTIVE: To help family physicians who care for patients with acute stroke or who are involved in planning service delivery or resource allocation to understand recent developments in acute stroke care. QUALITY OF EVIDENCE: A MEDLINE search indicated that most data were derived from well designed, randomized, double-blind, placebo-controlled trials, including all the largest international studies and large systematic reviews. MAIN MESSAGE: Treatment of acute stroke with tissue plasminogen activator seems beneficial for certain patients with certain kinds of stroke. Because thrombolytic therapy is not without risk and requires substantial resources, it should be administered only by physicians trained in its use and in centres with the necessary experience and resources. Because time is important, an organized and efficient system of stroke care with collaboration between hospital and prehospital care providers and help from ordinary citizens is essential.
CONCLUSION: Management of acute stroke is an emerging discipline; many potential therapies are still experimental.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570304      PMCID: PMC2018568     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  22 in total

1.  A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-08       Impact factor: 7.914

2.  Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment.

Authors:  R E O'Connor; P McGraw; L Edelsohn
Journal:  Ann Emerg Med       Date:  1999-01       Impact factor: 5.721

3.  Acute stroke: delays to presentation and emergency department evaluation.

Authors:  R Kothari; E Jauch; J Broderick; T Brott; L Sauerbeck; J Khoury; T Liu
Journal:  Ann Emerg Med       Date:  1999-01       Impact factor: 5.721

4.  Public perception of stroke warning signs and knowledge of potential risk factors.

Authors:  A M Pancioli; J Broderick; R Kothari; T Brott; A Tuchfarber; R Miller; J Khoury; E Jauch
Journal:  JAMA       Date:  1998 Apr 22-29       Impact factor: 56.272

5.  Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness.

Authors:  A M Buchan; P A Barber; N Newcommon; H G Karbalai; A M Demchuk; K M Hoyte; G M Klein; T E Feasby
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

6.  Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight.

Authors:  E C Haley; C Lewandowski; B C Tilley
Journal:  Ann Emerg Med       Date:  1997-11       Impact factor: 5.721

7.  Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies.

Authors:  T M Osborn; M P LaMonte; W R Gaasch
Journal:  Ann Emerg Med       Date:  1999-08       Impact factor: 5.721

8.  The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.

Authors:  T Steiner; E Bluhmki; M Kaste; D Toni; P Trouillas; R von Kummer; W Hacke
Journal:  Cerebrovasc Dis       Date:  1998 Jul-Aug       Impact factor: 2.762

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

Review 10.  Stroke--a medical emergency.

Authors:  C Lott; H J Hennes; W Dick
Journal:  J Accid Emerg Med       Date:  1999-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.